<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" media="screen" href="/~d/styles/rss2full.xsl"?><?xml-stylesheet type="text/css" media="screen" href="http://feeds.feedburner.com/~d/styles/itemcontent.css"?><rss xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd" xmlns:feedburner="http://rssnamespace.org/feedburner/ext/1.0" version="2.0">
      <channel>
        <title>Latest articles from MPR New Drug Products</title>
        <link>http://www.empr.com</link>
        <description>Latest articles from MPR New Drug Products</description>
        <itunes:author>MPR</itunes:author>
        <itunes:subtitle>New Drug Products</itunes:subtitle>
        <itunes:summary>New drug products, written in a concise and up-to-date style, from the drug information experts at MPR.</itunes:summary>
        <itunes:owner>
            <itunes:name>New Drug Products</itunes:name>
            <itunes:email>custserv@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href="http://media.empr.com/images/2009/12/22/mpr_mobile_83145.png" />
        <itunes:explicit>no</itunes:explicit>
  
        <atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="self" type="application/rss+xml" href="http://feeds.feedburner.com/MPRNewDrugProducts" /><feedburner:info uri="mprnewdrugproducts" /><atom10:link xmlns:atom10="http://www.w3.org/2005/Atom" rel="hub" href="http://pubsubhubbub.appspot.com/" /><feedburner:browserFriendly></feedburner:browserFriendly><item>
          <title>KADCYLA</title>
          <description>Ado-trastuzumab emtansine 100mg, 160mg; per vial; powder; for IV infusion after reconstitution.</description>
          <link>http://www.empr.com/kadcyla/drugproduct/267/</link>
          <pubDate>Sun, 12 May 2013 14:00:00 GMT</pubDate>
          <itunes:summary>Ado-trastuzumab emtansine 100mg, 160mg; per vial; powder; for IV infusion after reconstitution.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>INVOKANA</title>
          <description>Canagliflozin 100mg, 300mg; tablets.</description>
          <link>http://www.empr.com/invokana/drugproduct/270/</link>
          <pubDate>Sun, 05 May 2013 14:00:00 GMT</pubDate>
          <itunes:summary>Canagliflozin 100mg, 300mg; tablets.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>AUVI-Q</title>
          <description>Epinephrine 0.3mg, 0.15mg; pre-filled auto-injector (includes audible and visible cues for use).</description>
          <link>http://www.empr.com/auvi-q/drugproduct/268/</link>
          <pubDate>Sun, 28 Apr 2013 14:01:00 GMT</pubDate>
          <itunes:summary>Epinephrine 0.3mg, 0.15mg; pre-filled auto-injector (includes audible and visible cues for use).</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>VARIZIG</title>
          <description>Varicella zoster immune globulin (human) 125 IU; per vial; lyophilized pwd for IM inj after reconstitution; contains &lt;250mg of total protein (mostly human IgG), &lt;40mcg/mL of IgA; preservative- and mercury-free.</description>
          <link>http://www.empr.com/varizig/drugproduct/266/</link>
          <pubDate>Sun, 21 Apr 2013 14:06:00 GMT</pubDate>
          <itunes:summary>Varicella zoster immune globulin (human) 125 IU; per vial; lyophilized pwd for IM inj after reconstitution; contains &lt;250mg of total protein (mostly human IgG), &lt;40mcg/mL of IgA; preservative- and mercury-free.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>MINIVELLE</title>
          <description>Estradiol 0.0375mg/day, 0.05mg/day, 0.075mg/day, 0.1mg/day; transdermal patch.</description>
          <link>http://www.empr.com/minivelle/drugproduct/265/</link>
          <pubDate>Sun, 14 Apr 2013 14:11:00 GMT</pubDate>
          <itunes:summary>Estradiol 0.0375mg/day, 0.05mg/day, 0.075mg/day, 0.1mg/day; transdermal patch.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>SIGNIFOR</title>
          <description>Pasireotide diaspartate 0.3mg/mL, 0.6mg/mL, 0.9mg/mL; soln for SC inj.</description>
          <link>http://www.empr.com/signifor/drugproduct/264/</link>
          <pubDate>Sun, 07 Apr 2013 19:23:00 GMT</pubDate>
          <itunes:summary>Pasireotide diaspartate 0.3mg/mL, 0.6mg/mL, 0.9mg/mL; soln for SC inj.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>MARQIBO</title>
          <description>Vincristine sulfate liposome injection; after preparation, each vial contains 0.16mg/mL; for IV infusion.</description>
          <link>http://www.empr.com/marqibo/drugproduct/262/</link>
          <pubDate>Sun, 31 Mar 2013 13:19:00 GMT</pubDate>
          <itunes:summary>Vincristine sulfate liposome injection; after preparation, each vial contains 0.16mg/mL; for IV infusion.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>ICLUSIG</title>
          <description>Ponatinib 15mg, 45mg; tabs.</description>
          <link>http://www.empr.com/iclusig/drugproduct/261/</link>
          <pubDate>Sun, 24 Mar 2013 12:32:00 GMT</pubDate>
          <itunes:summary>Ponatinib 15mg, 45mg; tabs.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>SKYLA</title>
          <description>Levonorgestrel 13.5mg; intrauterine system.</description>
          <link>http://www.empr.com/skyla/drugproduct/260/</link>
          <pubDate>Sun, 17 Mar 2013 14:00:00 GMT</pubDate>
          <itunes:summary>Levonorgestrel 13.5mg; intrauterine system.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>RAYOS</title>
          <description>Prednisone 1mg, 2mg, 5mg; delayed-release tablets.</description>
          <link>http://www.empr.com/rayos/drugproduct/259/</link>
          <pubDate>Sun, 10 Mar 2013 13:07:00 GMT</pubDate>
          <itunes:summary>Prednisone 1mg, 2mg, 5mg; delayed-release tablets.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>SYNRIBO</title>
          <description>Omacetaxine mepesuccinate 3.5mg/vial; lyophilized powder for SC injection after reconstitution; contains mannitol; ­preservative-free.</description>
          <link>http://www.empr.com/synribo/drugproduct/258/</link>
          <pubDate>Sun, 03 Mar 2013 14:05:00 GMT</pubDate>
          <itunes:summary>Omacetaxine mepesuccinate 3.5mg/vial; lyophilized powder for SC injection after reconstitution; contains mannitol; ­preservative-free.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>ELIQUIS</title>
          <description>Apixaban 2.5mg, 5mg; tablets.</description>
          <link>http://www.empr.com/eliquis/drugproduct/256/</link>
          <pubDate>Sun, 24 Feb 2013 15:00:00 GMT</pubDate>
          <itunes:summary>Apixaban 2.5mg, 5mg; tablets.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>UCERIS</title>
          <description>Budesonide 9mg; extended-release tabs.</description>
          <link>http://www.empr.com/uceris/drugproduct/255/</link>
          <pubDate>Sun, 17 Feb 2013 15:00:00 GMT</pubDate>
          <itunes:summary>Budesonide 9mg; extended-release tabs.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>OXTELLAR XR</title>
          <description>Oxcarbazepine 150mg, 300mg, 600mg; extended-release tablets.</description>
          <link>http://www.empr.com/oxtellar-xr/drugproduct/254/</link>
          <pubDate>Sun, 10 Feb 2013 14:47:00 GMT</pubDate>
          <itunes:summary>Oxcarbazepine 150mg, 300mg, 600mg; extended-release tablets.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>VASCEPA</title>
          <description>Icosapent ethyl 1g; soft gelatin capsules.</description>
          <link>http://www.empr.com/vascepa/drugproduct/253/</link>
          <pubDate>Sun, 03 Feb 2013 14:52:00 GMT</pubDate>
          <itunes:summary>Icosapent ethyl 1g; soft gelatin capsules.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>QUILLIVANT XR</title>
          <description>Methylphenidate HCl extended-release 5mg/mL; pwd for oral suspension after reconstitution.</description>
          <link>http://www.empr.com/quillivant-xr/drugproduct/252/</link>
          <pubDate>Sun, 27 Jan 2013 15:00:00 GMT</pubDate>
          <itunes:summary>Methylphenidate HCl extended-release 5mg/mL; pwd for oral suspension after reconstitution.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>COMETRIQ</title>
          <description>Cabozantinib 20mg, 80mg; caps.</description>
          <link>http://www.empr.com/cometriq/drugproduct/251/</link>
          <pubDate>Sun, 20 Jan 2013 14:16:00 GMT</pubDate>
          <itunes:summary>Cabozantinib 20mg, 80mg; caps.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>ULTRESA 13800</title>
          <description>Lipase 13800, protease 27600, amylase 27600; del-rel caps; e-c minitabs in caps.</description>
          <link>http://www.empr.com/ultresa-13800/drugproduct/250/</link>
          <pubDate>Sun, 13 Jan 2013 14:21:00 GMT</pubDate>
          <itunes:summary>Lipase 13800, protease 27600, amylase 27600; del-rel caps; e-c minitabs in caps.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>JUXTAPID</title>
          <description>Lomitapide mesylate 5mg, 10mg, 20mg; caps.</description>
          <link>http://www.empr.com/juxtapid/drugproduct/249/</link>
          <pubDate>Sun, 06 Jan 2013 14:15:00 GMT</pubDate>
          <itunes:summary>Lomitapide mesylate 5mg, 10mg, 20mg; caps.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>XELJANZ</title>
          <description>Tofacitinib 5mg tabs.</description>
          <link>http://www.empr.com/xeljanz/drugproduct/248/</link>
          <pubDate>Sun, 23 Dec 2012 15:00:00 GMT</pubDate>
          <itunes:summary>Tofacitinib 5mg tabs.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>AUVI-Q</title>
          <description>Indication(s):

Emergency treatment of allergic reactions (Type 1) including anaphylaxis.</description>
          <link>http://www.empr.com/new-drug-product-auvi-q/slideshow/1291/</link>
          <pubDate>Mon, 01 Jan 0001 05:00:00 GMT</pubDate>
          <itunes:summary>Indication(s):

Emergency treatment of allergic reactions (Type 1) including anaphylaxis.</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
        <item>
          <title>INVOKANA</title>
          <description>Indication(s):

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).</description>
          <link>http://www.empr.com/new-drug-product-invokana/slideshow/1308/</link>
          <pubDate>Mon, 01 Jan 0001 05:00:00 GMT</pubDate>
          <itunes:summary>Indication(s):

Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (T2DM).</itunes:summary>
          <itunes:author>MPR</itunes:author>
          
        </item>
  
      </channel>
    </rss>
